Aspiropharma - Due diligence report

A 360° intelligence report on Aspiropharma: trust score, financial health, credit view, compliance, directors, growth and distress signals -…

2014-02-05 Markook, Telangana Active Unlisted Active Compliant
Share
Connect MCP
AS Aspiropharma
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Aspiropharma — 360° Intelligence Report

Generated from MCA filings & public records
86/100
Trust Score
Low Risk

Aspiropharma is assessed as Low Risk with a Trust Score of 86/100. Aspiropharma is an active public limited indian non-government company incorporated in 2014, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 22 Sep 2026 from the latest processed filings. Aspiro Pharma Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
86/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
85/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
35/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 35/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 15 open (206.91 cr) · 1 satisfied (46.89 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others11 48.0 cr
State Bank Of Mysore1 48.0 cr
Hdfc Bank Limited4 48.0 cr
Compliance Score: 85/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (17 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
BANDI VAMSIKRISHNA 01234567 Director 01/04/2018 6 yrs Approved
REDDY NARSIMHA 01234567 Director 01/04/2018 6 yrs Approved
SRINIVAS DAKARAPU 01234567 Director 01/04/2018 6 yrs Approved
KRISHNAVENI KURA 01234567 Director 01/04/2018 6 yrs Approved
RAMASESHAPPA SIVA PRASAD PANCHANGAM 01234567 Director 01/04/2018 6 yrs Approved
SUDERSHAN PALLAP 01234567 Director 01/04/2018 6 yrs Approved
MAHESH RAMAPPA KAMALAMMA HASSAN 01234567 Director 01/04/2018 6 yrs Approved
BHASKARREDDY PABBATIREDDY 01234567 Director 01/04/2018 6 yrs Approved
Dakarapu Srinivas 01234567 Director 01/04/2018 6 yrs Approved
  • 9 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Hetero Labs Limited
Subsidiaries
1
Group entities
1
Capital events
9 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Strivo Pharma Private Limited Subsidiary Company 74.00%
Hetero Labs Limited Holding Company 74.00%

Key managerial personnel: SRINIVAS DAKARAPU (CFO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
Net margin improved to 38%.
EPFO headcount growing - hiring signal.
Operating for 12+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 1.42 in a year.
15 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 27.82 Lakh.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence84/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment61/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 15 open charge(s) of 206.91 cr already registered.
  • Compliance record supports lending.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 6 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
10 Oct 2025
Director appointed
BHASKARREDDY PABBATIREDDY (Additional Director)
24 Jul 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
18 Nov 2024
Charge satisfied
State Bank Of Mysore
30 Sep 2024
Charge created
Others - 100.00 cr
18 Aug 2024
Director ceased
REDDY NARSIMHA
03 Aug 2024
Director appointed
REDDY NARSIMHA (Director)
10 May 2024
Charge created
Others - 9.00 Lakh
03 Apr 2024
Charge created
Others - 105.00 cr
04 Nov 2023
Charge created
Others - 13.00 Lakh
26 Oct 2023
Charge created
Others - 10.24 Lakh
22 Sep 2023
Director ceased
MAHESH RAMAPPA KAMALAMMA HASSAN
03 Aug 2023
Director appointed
RAMASESHAPPA SIVA PRASAD PANCHANGAM (Director)
07 Jun 2023
Director appointed
MAHESH RAMAPPA KAMALAMMA HASSAN (Director)
01 Jun 2023
Charge created
Others - 18.91 Lakh
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
9 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 9 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Assam Petro Chemicals Ltd U24116AS1971SGC001339 Gmc, Assam, India
Mazda Colours U24114MH1972PLC015706 Mumbai, Maharashtra, India
Ashapura Perfoclay Limited U14108MH1997PLC107300 Mumbai, Maharashtra, India
Resil U24114KA1991PTC041568 Bangalore, Karnataka, India
Sun Pharmaceutical Medicare Limited U36900GJ2017PLC095132 Vadodara, Gujarat, India
Pelgel L24110TG1980PLC002633 Secunderabad, Andhra Pradesh, India
Recipharm U24230MH2015PTC440983 Mumbai, Maharashtra, India
R M Phosphates & Chemicals Private Limited U24100MH2010PTC208728 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Aspiropharma before audits and certifications: compliance score 85/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Aspiropharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 35/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Aspiropharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 86/100, distress signals and MSME payment-delay disclosures - know whether Aspiropharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Aspiropharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Aspiropharma an active company?

Aspiropharma has MCA status “Active” with a compliance score of 85/100 (Low Risk).

Is Aspiropharma financially healthy?

Aspiropharma has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Aspiropharma?

Its overall Trust Score is 86/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Aspiropharma?

The ultimate holding entity is Hetero Labs Limited. 9 active director(s) are on record.

Does Aspiropharma have loans or charges against its assets?

15 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Aspiropharma up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 85/100 (Low Risk).

Is it risky to lend to Aspiropharma?

Its Credit Risk Score is 35/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.